Literature DB >> 31773009

Proton Therapy Reduces Normal Tissue Dose in Extended-Field Pelvic Radiation for Endometrial Cancer.

Melody J Xu1, Alisha Maity2, Jennifer Vogel3, Maura Kirk3, Huifang Zhai3, Stefan Both4, Lilie L Lin5.   

Abstract

PURPOSE: We dosimetrically compared pencil beam scanning (PBS) proton therapy and intensity-modulated radiation therapy (IMRT) for pelvic and para-aortic lymph node disease in endometrial carcinoma and present acute toxicities associated with extended-field PBS. PATIENTS AND METHODS: Twenty-five patients with locally advanced endometrial malignancies were enrolled in an image-guided registry study. Seven of these patients were treated with PBS, and 18 patients were treated with IMRT. Organs at risk included pelvic bone marrow (PBM), small bowel (SB), large bowel (LB), rectum, bladder, and kidneys. The IMRT and PBS dosimetric parameters were compared using Wilcoxon rank-sum tests.
RESULTS: Compared with IMRT PBM dose-volume histograms, PBS resulted in significantly lower dose volumes from 0 to 26.0 Gy (P < .05) and higher dose volumes from 33.9 to 42.9 Gy (P < .05). Overall, PBS resulted in 22% lower median PBM volume irradiated to 10 Gy (RBE) (PBS 71.3% versus IMRT 93.4%, P < .001) and 14% lower median volume irradiated to 20 Gy (RBE) (PBS 65.1% versus IMRT 79.4%, P < .001). Compared with IMRT, PBS also significantly reduced SB dose volumes from 0 to 27.5 Gy, LB dose volumes from 0 to 31.6 Gy, bladder dose volumes from 0 to 27.3 Gy, and rectal dose volumes from 0 to 7.6 Gy (all P < .05). However, PBS resulted in higher rectal dose volumes compared with IMRT from 26.0 to 48.4 Gy. Grade 3+ hematologic toxicities were present in 2 (11%) IMRT-treated patients and no PBS-treated patients. No grade 3+ gastrointestinal or genitourinary toxicities were present in either treatment group.
CONCLUSION: In endometrial carcinoma, extended-field PBS is clinically feasible, resulting in statistically significant dose reduction to PBM as well as SB, LB, and bladder in the lower dose regions. © Copyright 2017 International Journal of Particle Therapy 2018.

Entities:  

Keywords:  endometrial carcinoma; extended field pelvic radiotherapy; pelvic bone marrow; proton therapy

Year:  2018        PMID: 31773009      PMCID: PMC6871568          DOI: 10.14338/IJPT-17-00027.1

Source DB:  PubMed          Journal:  Int J Part Ther        ISSN: 2331-5180


  18 in total

1.  The distribution of active bone marrow in the adult.

Authors:  R E ELLIS
Journal:  Phys Med Biol       Date:  1961-01       Impact factor: 3.609

2.  Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.

Authors:  Loren K Mell; Joel D Kochanski; John C Roeske; Josh J Haslam; Neil Mehta; S Diane Yamada; Jean A Hurteau; Yvonne C Collins; Ernst Lengyel; Arno J Mundt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-06       Impact factor: 7.038

3.  Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: results of the phase II RTCMIENDOMETRE French multicentre trial.

Authors:  Isabelle Barillot; Elsa Tavernier; Karine Peignaux; Danièle Williaume; Philippe Nickers; Magali Leblanc-Onfroy; Delphine Lerouge
Journal:  Radiother Oncol       Date:  2014-03-11       Impact factor: 6.280

4.  Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.

Authors:  Brent S Rose; Bulent Aydogan; Yun Liang; Mete Yeginer; Michael D Hasselle; Virag Dandekar; Rounak Bafana; Catheryn M Yashar; Arno J Mundt; John C Roeske; Loren K Mell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-17       Impact factor: 7.038

5.  Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer.

Authors:  William Small; Loren K Mell; Penny Anderson; Carien Creutzberg; Jennifer De Los Santos; David Gaffney; Anuja Jhingran; Lorraine Portelance; Tracey Schefter; Revathy Iyer; Mahesh Varia; Kathryn Winter; Arno J Mundt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-26       Impact factor: 7.038

6.  Concomitant cisplatin and extended field radiation therapy in patients with cervical and endometrial cancer.

Authors:  B M Sood; P F Timmins; G R Gorla; M Garg; P S Anderson; B Vikram; G L Goldberg
Journal:  Int J Gynecol Cancer       Date:  2002 Sep-Oct       Impact factor: 3.437

7.  Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy.

Authors:  Chien-Chih Chen; Lily Wang; Chien-Hsing Lu; Jin-Ching Lin; Jian-Sheng Jan
Journal:  J Formos Med Assoc       Date:  2013-10-18       Impact factor: 3.282

8.  Are Radiation Therapy Oncology Group Para-aortic Contouring Guidelines for Pancreatic Neoplasm applicable to other malignancies--assessment of nodal distribution in gynecological malignancies.

Authors:  Peyman Kabolizadeh; Suyash Fulay; Sushil Beriwal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-07-09       Impact factor: 7.038

9.  Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.

Authors:  Philip D Poorvu; Cheryl A Sadow; Kanokpis Townamchai; Antonio L Damato; Akila N Viswanathan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-20       Impact factor: 7.038

10.  Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer.

Authors:  Shervin M Shirvani; Ann H Klopp; Anna Likhacheva; Anuja Jhingran; Pamela T Soliman; Karen H Lu; Patricia J Eifel
Journal:  Pract Radiat Oncol       Date:  2012-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.